All lobbying filings
Bravo Group
Bravo Group filed a Q3 report for Pharmaceutical Research and Manufacturers of America on October 19, 2026, reporting $30,000 in lobbying income.
Lobbying for Pharmaceutical Research and Manufacturers of America · Advocacy
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Income
$30,000
What the client paid this registrant for the period.
Client based in
District of Columbia
Lobbyists on this filing
1
-
BRANDON FERRANCEPreviously held: Congressional Intern, Staff Assistant, Press Assistant
Government bodies contacted
2
Lobbying activity
1
Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.